HomepageEarnings Events Newsdesk 2 hours ago Eli Lilly and Company (LLY) Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release Pfizer inc (PFE) TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer » « 3M Company (MMM) 3M To Create A Leading Fire And Safety Business; Acquires Madison Fire & Rescue And Combines With Scott Safety Newsdesk: